BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,693 Shares of Stock

Posted by Brenda Bartman on Jun 19th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 3,693 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $265.55, for a total value of $980,676.15. Following the completion of the transaction, the chief executive officer owned 2,043 shares in the company, valued at approximately $542,518.65. The trade was a 64.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Up 2.8%

Shares of NASDAQ:ONC opened at $270.15 on Friday. The stock has a market cap of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. The firm has a fifty day moving average price of $296.16 and a 200 day moving average price of $312.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ONC. Mariner LLC lifted its holdings in BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after acquiring an additional 32 shares during the period. Signaturefd LLC grew its stake in shares of BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after purchasing an additional 33 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of BeOne Medicines by 21.8% in the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after purchasing an additional 39 shares in the last quarter. CWM LLC increased its holdings in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its stake in shares of BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wolfe Research began coverage on BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 price target for the company. Guggenheim lifted their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. Finally, Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Read Our Latest Stock Report on ONC

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.